Immunic, inc. announces positive top-line data from investigator-sponsored phase 2 proof-of-concept clinical trial of imu-838 in primary sclerosing cholangitis

New york, feb. 18, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an...
IMUX Ratings Summary
IMUX Quant Ranking